HHS · no agency ID · record R0853

AI-assisted Platform for Clinical Pharmacology Review

Department of Health and Human Services · HHS/FDA/CDER

Overview

Development stage: In development or acquisitionSource: a) Pre-deployment – The use case is in a development or acquisition status.
High-impact designation: Not high-impactSource: c) Not high-impact
Impact justification: Not reported
Start date: Not reported
Withheld from public reporting: NoSource: a) No

Mission

Topic area: Health and Medical
Operational functions: Clinical and medical Derived by keyword rules; see methodology

Problem the AI is intended to solve

The AI solution addresses inefficiency in the clinical pharmacology review process by reducing time reviewers spend on routine tasks, allowing them to focus their expertise on complex scientific analysis and decision-making that truly requires their specialized knowledge.

Expected benefits

The AI integration is expected to enhance agency efficiency by optimizing reviewer time allocation, allowing them to focus on high-value tasks requiring specialized expertise. This leads to improved productivity, reduced delays, and enhanced overall performance. For the public, this translates to more timely and higher quality regulatory reviews of new medications.

System outputs

AI assisted answers to list of tasks in selected task groups for clinical pharmacology review, including supporting information helping reviewers to identify the source of information from original documents.

Technology

AI classification: Generative AISource: Generative AI: AI that generates new or synthetic content (e.g., images, videos, audio, text, code).
System name(s): Not reported
Custom-developed code: Not reported
Public source code: Not reported

Sourcing

How it was built: Not reported
Vendor (as reported): Not reported
Vendors (standardized): None on the standard list

A vendor is the supplier named by the agency. It does not identify the underlying model or AI technology.

Data and privacy

Involves PII: Not reported
Privacy Impact Assessment: Not reported
Authorization to Operate: Not reported
Demographic features: Not reported
Training and evaluation data: Not reported
Federal Data Catalog: Not reported

Governance

0 of 8 minimum-practice questions answered. A blank answer means the agency reported nothing; it does not mean the practice is absent.

Pre-deployment testingNo answer reported

AI impact assessmentNo answer reported

Independent reviewNo answer reported

Ongoing monitoringNo answer reported

Operator trainingNo answer reported

Fail-safeNo answer reported

Appeal processNo answer reported

User and public consultationNo answer reported

Potential impacts and how they were identified

Not reported